YMC completes acquisition of LEWA Bioprocess system

The products, staff and facilities associated with “Devens, MA USA” component of LEWA Nikkiso America, Inc. were acquired by YMC.

The products, staff and facilities associated with “Devens, MA USA” component of LEWA Nikkiso America, Inc. were acquired by YMC. This made up the global bio/pharmaceutical systems business of LEWA. The deal included the EcoPrime LPLC, BID, Twin, SMB and other OEM products traditionally produced by the Devens’ site (the former IPT/LPT). YMC acquired the know-how, resources and good will of the existing Devens’ business. YMC also inherited several license arrangements such as certain ChromaCon continuous chromatography patented process methods and Bayer Technology Services (BTS) license for simulated moving bed (SMB) along with access to certain other patented products. LEWA will remain a key supply-partner of pumps as part of the deal.

YMC saw this business as a well-regarded growth platform of advanced bio / pharma GMP scale systems, leading the trend in GMP scale multi-column (continuous) chromatography. These technologies paired well with YMC’s leading resins, gels and columns. YMC was looking to expand their hardware business in the American and European markets which was an established market for the EcoPrime TWIN, LPLC, HPLC and BID (Buffer Dilution) system business. YMC also desired a USA based manufacturing operation.

YMC is a technology and services supplier to the pharmaceutical / biopharmaceutical industry since 1980. With around 400 employees focused on technologies to support the development and production of drug therapies in all major global geographies, YMC is a privately held, growth oriented company with a balanced consumables, hardware and services strategy. They have a robust portfolio of (chromatography) media / resin, columns and systems for both research and production scale applications.